[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2022192594A3 - Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease - Google Patents

Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease Download PDF

Info

Publication number
WO2022192594A3
WO2022192594A3 PCT/US2022/019834 US2022019834W WO2022192594A3 WO 2022192594 A3 WO2022192594 A3 WO 2022192594A3 US 2022019834 W US2022019834 W US 2022019834W WO 2022192594 A3 WO2022192594 A3 WO 2022192594A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
acid molecules
vaccines
disease
prevention
Prior art date
Application number
PCT/US2022/019834
Other languages
French (fr)
Other versions
WO2022192594A2 (en
Inventor
Runqiang CHEN
Hui Xie
Henry Hongjun Ji
Qidong Hu
Hua Wang
David Francis
Russell F. Ross
Xiaoxuan LYU
Ying Zhao
Peng Wang
Haotian SUN
Ying Zeng
Original Assignee
Sorrento Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics, Inc. filed Critical Sorrento Therapeutics, Inc.
Publication of WO2022192594A2 publication Critical patent/WO2022192594A2/en
Publication of WO2022192594A3 publication Critical patent/WO2022192594A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present disclosure relates, inter alia, to nucleic acid molecules and compositions, pharmaceutical compositions, vaccines comprising such nucleic acid molecules for preventing or treating coronavirus infections and diseases associated therewith, as well as methods for administering same.
PCT/US2022/019834 2021-03-11 2022-03-10 Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease WO2022192594A2 (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US202163159972P 2021-03-11 2021-03-11
US63/159,972 2021-03-11
US202163228008P 2021-07-30 2021-07-30
US63/228,008 2021-07-30
US202163237133P 2021-08-25 2021-08-25
US63/237,133 2021-08-25
US202263298755P 2022-01-12 2022-01-12
US63/298,755 2022-01-12
US202263316329P 2022-03-03 2022-03-03
US63/316,329 2022-03-03

Publications (2)

Publication Number Publication Date
WO2022192594A2 WO2022192594A2 (en) 2022-09-15
WO2022192594A3 true WO2022192594A3 (en) 2022-11-24

Family

ID=80999550

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/019834 WO2022192594A2 (en) 2021-03-11 2022-03-10 Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease

Country Status (1)

Country Link
WO (1) WO2022192594A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
JP2023181989A (en) * 2022-06-13 2023-12-25 上海臻上医薬科技有限公司 Microneedle injection preparations and their uses
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US6938003B2 (en) 2000-06-30 2005-08-30 Mahesh Harpale Method and apparatus for a credibility reporting system to augment an online exchange
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
RU2585159C2 (en) 2010-04-28 2016-05-27 Кимберли-Кларк Ворлдвайд, Инк. Device for delivering drug used in rheumatoid arthritis
PT2563453T (en) 2010-04-28 2017-03-15 Kimberly Clark Co Nanopatterned medical device with enhanced cellular interaction and method for its forming
EP2563455A4 (en) 2010-04-28 2014-02-19 Kimberly Clark Co METHOD FOR INCREASING THE PERMEABILITY OF AN EPITHELIAL BARRIER
WO2011135531A2 (en) 2010-04-28 2011-11-03 Kimberly-Clark Worldwide, Inc. MEDICAL DEVICES FOR DELIVERY OF siRNA
KR20220051429A (en) 2011-10-27 2022-04-26 소렌토 쎄라퓨틱스, 인코포레이티드 Transdermal delivery of high viscosity bioactive agents
MX360121B (en) 2013-02-28 2018-10-03 Kimberly Clark Co Transdermal drug delivery device.
US9861801B2 (en) 2013-02-28 2018-01-09 Kimberly-Clark Worldwide, Inc. Drug delivery device
EP2999510A1 (en) 2013-05-23 2016-03-30 Kimberly-Clark Worldwide, Inc. Microneedles with improved open channel cross-sectional geometries
WO2015016821A1 (en) 2013-07-30 2015-02-05 Hewlett-Packard Development Company, L.P. Determining topic relevance of an email thread
CA2945003C (en) 2014-04-30 2022-08-09 Kimberly-Clark Worldwide, Inc. Receptacle portion of transdermal drug delivery apparatus and methods
US10111807B2 (en) 2014-04-30 2018-10-30 Sorrento Therapeutics, Inc. Cartridge portion of transdermal drug delivery apparatus and methods
MX376003B (en) 2014-04-30 2025-03-07 Vivasor Inc CONTROLLER PORTION OF A DEVICE AND METHODS FOR ADMINISTERING TRANSDERMAL MEDICINES.
AU2015253253B2 (en) 2014-04-30 2019-09-12 Sorrento Therapeutics, Inc. Transdermal drug delivery apparatus and methods
CN106163607B (en) 2014-04-30 2018-03-27 金伯利-克拉克环球有限公司 The microneedle array of drape
KR20170026467A (en) 2014-06-30 2017-03-08 킴벌리-클라크 월드와이드, 인크. Patterned surfaces
HUE056410T2 (en) 2015-07-24 2022-02-28 Sorrento Therapeutics Inc Methods for better delivery of drugs to tumors
US10737082B2 (en) 2015-07-24 2020-08-11 Sorrento Therapeutics, Inc. Methods for lymphatic delivery of active agents
US11311708B2 (en) 2016-04-29 2022-04-26 Sorrento Therapeutics, Inc. Microneedle array assembly and fluid delivery apparatus having such an assembly
AU2017258749B2 (en) 2016-04-29 2022-06-16 Vivasor, Inc. Microneedle array assembly, drug delivery device and method for administering liquid across a broad area at low pressure
ES2898083T3 (en) 2016-12-16 2022-03-03 Sorrento Therapeutics Inc Liquid Supply Apparatus and Assembly Procedure
AU2017376502B2 (en) 2016-12-16 2023-10-05 Vivasor, Inc. Method for administering a medicament suitable for treating a migraine or cluster headache
CN114681787A (en) 2016-12-16 2022-07-01 索伦托治疗有限公司 Fluid delivery device with controller assembly and method of use thereof
US10569010B2 (en) 2016-12-16 2020-02-25 Sorrento Therapeutics, Inc. Fluid delivery apparatus having a gas extraction device and method of use
AU2017378040B2 (en) 2016-12-16 2023-06-08 Vivasor, Inc. Application device for a fluid delivery apparatus and method of use
ES2912537T3 (en) 2016-12-16 2022-05-26 Sorrento Therapeutics Inc Support band for a fluid administration apparatus and method of use
MX2020012789A (en) 2018-05-31 2021-04-28 Sorrento Therapeutics Inc Drug delivery methods targeting the lymphatic system.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
POLACK FERNANDO P. ET AL: "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 383, no. 27, 31 December 2020 (2020-12-31), US, pages 2603 - 2615, XP055820495, ISSN: 0028-4793, Retrieved from the Internet <URL:https://pro.biontech.de/files/Polack_F_et_al.pdf> [retrieved on 20220822], DOI: 10.1056/NEJMoa2034577 *
SAHIN UGUR ET AL: "COVID-19 vaccine BNT162b1 elicits human antibody and T1 T cell responses", NATURE, NATURE PUBLISHING GROUP UK, LONDON, vol. 586, no. 7830, 30 September 2020 (2020-09-30), pages 594 - 599, XP037276953, ISSN: 0028-0836, [retrieved on 20200930], DOI: 10.1038/S41586-020-2814-7 *

Also Published As

Publication number Publication date
WO2022192594A2 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
MX2022015272A (en) Inhibitors of kras g12c protein and uses thereof.
MX2022015812A (en) Inhibitors of cysteine proteases and methods of use thereof.
MX2024000208A (en) Novel therapeutic delivery moieties and uses thereof.
BR112015014458A2 (en) mannose derivatives for the treatment of bacterial infections
WO2019133770A3 (en) Glycolate oxidase inhibitors for the treatment of disease
BR112015011497A2 (en) compound, pharmaceutical formulation, combination product, and method of treating a disease
MX2023003627A (en) 1,2,3,4-tetrahydroquinoline derivatives as inhibitors of the yap/taz-tead activation for treating cancer.
MX2023003678A (en) Hsd17b13 inhibitors and uses thereof.
AU2020231934A8 (en) Compounds useful in HIV therapy
WO2019217397A3 (en) Compositions and methods for improving strand biased
BR112022000505A2 (en) N-substituted 3,4-(5-fused-ring)-5-phenyl-pyrrolidin-2-one compounds as isoqc and/or qc enzyme inhibitors
EP4282414A3 (en) Modified release tablet formulations containing phosphodiesterase inhibitors
BR112019018615A2 (en) antimicrobial compounds, compositions and uses thereof
ZA202403388B (en) Small molecules for treatement of cancer
MX2023001296A (en) Compositions and methods for treating diseases and disorders.
MX2021009539A (en) 6-oxo-1,6-dihydropyridazine prodrug derivative, preparation method therefor, and application thereof in medicine.
BR112018072298A2 (en) treatment of Zika virus infections using alpha-glucosidase inhibitors
MX2024009403A (en) Tetrahydropyridopyrimidines and related analogs for inhibiting yap/taz-tead
WO2024175802A3 (en) SARS-CoV-2 NEUTRALIZING ANTIBODIES
WO2024102986A3 (en) Sars-cov-2 mpro inhibitors
MX2020012728A (en) Bio-based medicines and methods of increasing patient compliance.
WO2023164175A3 (en) Protacs of malt1
MX2024010408A (en) Dihydroquinazolinones and related analogs for inhibiting yap/taz-tead.
WO2023122316A3 (en) SPLICE SWITCH OLIGONUCLEOTIDE (SSO) MOLECULES FOR TARGETING β-CATENIN AND USES THEREOF

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22714055

Country of ref document: EP

Kind code of ref document: A2